Advanced Glycation Products and Vascular Complications in Type 1 Diabetes
Launched by CHU DE REIMS · Jun 10, 2024
Trial Information
Current as of November 10, 2025
Recruiting
Keywords
ClinConnect Summary
The clinical trial titled "Advanced Glycation Products and Vascular Complications in Type 1 Diabetes" is studying how certain substances in the body, known as Advanced Glycation End products (AGEs), are related to blood vessel problems in people with type 1 diabetes. This research is a follow-up to a previous study done between 2015 and 2017, which involved 196 patients who had lived with type 1 diabetes for over 10 years. The earlier study found that higher levels of these AGEs were linked to more vascular complications, and this new trial aims to explore that connection further.
If you are considering participating in this trial, you need to have been part of the original DIABAGE study and be willing to follow up at Reims hospital. People of any gender between the ages of 65 and 74 may be eligible. Participants can expect to undergo regular health assessments related to their diabetes and potential complications. This research is important because it could help improve our understanding of how to better manage diabetes and prevent related health issues.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Inclusion in initial DIABAGE study.
- • Follow-up at Reims hospital.
- Exclusion Criteria:
- • - Refusal to participate.
About Chu De Reims
Chu de Reims, or the University Hospital of Reims, is a leading healthcare institution in France dedicated to advancing medical research and improving patient care through innovative clinical trials. As a prominent clinical trial sponsor, Chu de Reims focuses on a wide range of therapeutic areas, fostering collaboration between multidisciplinary teams of healthcare professionals and researchers. The hospital is committed to adhering to the highest ethical standards and regulatory guidelines, ensuring that all trials are designed to deliver reliable data while prioritizing patient safety and well-being. Through its robust research infrastructure, Chu de Reims aims to contribute significantly to the advancement of medical knowledge and the development of new treatment options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Reims, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported